Aripiprazole augmentation for major depressive disorder

Dosing patterns in a naturalistic treatment setting

Chi Un Pae, Sheng Min Wang, Changsu Han, Soo Jung Lee, Ashwin A. Patkar, Prakash S. Masand

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This study investigated the dosing patterns for aripiprazole augmentation for major depressive disorder (MDD) in a naturalistic treatment setting. Between 1 January 2009 and 31 March 2012, patients with a diagnosis of MDD who were receiving aripiprazole augmentation in conjunction with an ongoing antidepressant were recruited for this study. The electronic medical records and clinical data for a total of 276 patients were reviewed up to a year. The mean duration of aripiprazole augmentation was ∼5 months; the mean time to the first increase of aripiprazole was about 3 weeks; and the mean initial, first up-titrated, maximal, and maintenance doses were 3.4, 4.2, 4.7, and 4.4 mg/day, respectively. The most frequent adverse events were insomnia, followed by anxiety and sedation. The current results indicate that the actual doses of aripiprazole augmentation with ongoing antidepressant for MDD should be lower than the doses used in placebo-controlled clinical trials and those recommended by the US Food and Drug Administration. Adequately powered and well-controlled prospective studies are needed to better understand the exact role of low doses of aripiprazole augmentation in the treatment of MDD, particularly in routine practice.

Original languageEnglish
Pages (from-to)116-119
Number of pages4
JournalInternational Clinical Psychopharmacology
Volume29
Issue number2
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Major Depressive Disorder
Antidepressive Agents
Therapeutics
Electronic Health Records
Controlled Clinical Trials
Sleep Initiation and Maintenance Disorders
United States Food and Drug Administration
Aripiprazole
Anxiety
Placebos
Prospective Studies

Keywords

  • Aripiprazole
  • Atypical Antipsychotics
  • Augmentation
  • Doses
  • Major Depressive Disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Aripiprazole augmentation for major depressive disorder : Dosing patterns in a naturalistic treatment setting. / Pae, Chi Un; Wang, Sheng Min; Han, Changsu; Lee, Soo Jung; Patkar, Ashwin A.; Masand, Prakash S.

In: International Clinical Psychopharmacology, Vol. 29, No. 2, 01.03.2014, p. 116-119.

Research output: Contribution to journalArticle

Pae, Chi Un ; Wang, Sheng Min ; Han, Changsu ; Lee, Soo Jung ; Patkar, Ashwin A. ; Masand, Prakash S. / Aripiprazole augmentation for major depressive disorder : Dosing patterns in a naturalistic treatment setting. In: International Clinical Psychopharmacology. 2014 ; Vol. 29, No. 2. pp. 116-119.
@article{866b6ef8b3fe451491383844c212e33b,
title = "Aripiprazole augmentation for major depressive disorder: Dosing patterns in a naturalistic treatment setting",
abstract = "This study investigated the dosing patterns for aripiprazole augmentation for major depressive disorder (MDD) in a naturalistic treatment setting. Between 1 January 2009 and 31 March 2012, patients with a diagnosis of MDD who were receiving aripiprazole augmentation in conjunction with an ongoing antidepressant were recruited for this study. The electronic medical records and clinical data for a total of 276 patients were reviewed up to a year. The mean duration of aripiprazole augmentation was ∼5 months; the mean time to the first increase of aripiprazole was about 3 weeks; and the mean initial, first up-titrated, maximal, and maintenance doses were 3.4, 4.2, 4.7, and 4.4 mg/day, respectively. The most frequent adverse events were insomnia, followed by anxiety and sedation. The current results indicate that the actual doses of aripiprazole augmentation with ongoing antidepressant for MDD should be lower than the doses used in placebo-controlled clinical trials and those recommended by the US Food and Drug Administration. Adequately powered and well-controlled prospective studies are needed to better understand the exact role of low doses of aripiprazole augmentation in the treatment of MDD, particularly in routine practice.",
keywords = "Aripiprazole, Atypical Antipsychotics, Augmentation, Doses, Major Depressive Disorder",
author = "Pae, {Chi Un} and Wang, {Sheng Min} and Changsu Han and Lee, {Soo Jung} and Patkar, {Ashwin A.} and Masand, {Prakash S.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1097/YIC.0000000000000012",
language = "English",
volume = "29",
pages = "116--119",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Aripiprazole augmentation for major depressive disorder

T2 - Dosing patterns in a naturalistic treatment setting

AU - Pae, Chi Un

AU - Wang, Sheng Min

AU - Han, Changsu

AU - Lee, Soo Jung

AU - Patkar, Ashwin A.

AU - Masand, Prakash S.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - This study investigated the dosing patterns for aripiprazole augmentation for major depressive disorder (MDD) in a naturalistic treatment setting. Between 1 January 2009 and 31 March 2012, patients with a diagnosis of MDD who were receiving aripiprazole augmentation in conjunction with an ongoing antidepressant were recruited for this study. The electronic medical records and clinical data for a total of 276 patients were reviewed up to a year. The mean duration of aripiprazole augmentation was ∼5 months; the mean time to the first increase of aripiprazole was about 3 weeks; and the mean initial, first up-titrated, maximal, and maintenance doses were 3.4, 4.2, 4.7, and 4.4 mg/day, respectively. The most frequent adverse events were insomnia, followed by anxiety and sedation. The current results indicate that the actual doses of aripiprazole augmentation with ongoing antidepressant for MDD should be lower than the doses used in placebo-controlled clinical trials and those recommended by the US Food and Drug Administration. Adequately powered and well-controlled prospective studies are needed to better understand the exact role of low doses of aripiprazole augmentation in the treatment of MDD, particularly in routine practice.

AB - This study investigated the dosing patterns for aripiprazole augmentation for major depressive disorder (MDD) in a naturalistic treatment setting. Between 1 January 2009 and 31 March 2012, patients with a diagnosis of MDD who were receiving aripiprazole augmentation in conjunction with an ongoing antidepressant were recruited for this study. The electronic medical records and clinical data for a total of 276 patients were reviewed up to a year. The mean duration of aripiprazole augmentation was ∼5 months; the mean time to the first increase of aripiprazole was about 3 weeks; and the mean initial, first up-titrated, maximal, and maintenance doses were 3.4, 4.2, 4.7, and 4.4 mg/day, respectively. The most frequent adverse events were insomnia, followed by anxiety and sedation. The current results indicate that the actual doses of aripiprazole augmentation with ongoing antidepressant for MDD should be lower than the doses used in placebo-controlled clinical trials and those recommended by the US Food and Drug Administration. Adequately powered and well-controlled prospective studies are needed to better understand the exact role of low doses of aripiprazole augmentation in the treatment of MDD, particularly in routine practice.

KW - Aripiprazole

KW - Atypical Antipsychotics

KW - Augmentation

KW - Doses

KW - Major Depressive Disorder

UR - http://www.scopus.com/inward/record.url?scp=84895076310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895076310&partnerID=8YFLogxK

U2 - 10.1097/YIC.0000000000000012

DO - 10.1097/YIC.0000000000000012

M3 - Article

VL - 29

SP - 116

EP - 119

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 2

ER -